Search

Searching with a thematic focus on HIV and AIDS, ARVs, HIV and AIDS treatment and care

Showing 121-130 of 162 results

Pages

• Document

  Treating 3 million by 2005: making it happen, the WHO strategy

  World Health Organization, 2003

  In 2001, partners within the Joint United Nations Programme on HIV/AIDS (UNAIDS) and other organisations along with scientists at the World Health Organization (WHO) calculated that, under optimal conditions, 3 million people living in developing countries could be provided with antiretroviral therapy and access to medical services by the end of 2005.
• Document

  Emergency scale-up of ART in resource-limited settings: technical and operational recommendations to achieve “3 by 5”

  World Health Organization, 2003

  This document is intended to help those implementing ART programs in resourcelimited settings accelerate their work, by identifying recommendations and priority actions that are required to deliver ART now.
• Document

  Therapies: confronting the limits of success

  AIDScience, 2002

  This article reports on the prevailing mood about the successes and limitations of antiretroviral drugs. The author charts the development of different drug strategies since 1996 (when a cocktail of drugs was first shown to control HIV), and canvasses expert opinion on their successes and limitations.The author argues that while the 16 different anti-HIV drugs now approved by the U.S.
• Document

  Decrease in prices of antiretroviral drugs for developing countries: from political “philanthropy” to regulated markets?

  International AIDS Economics Network, 2003

  This paper gives some economic background about recent debates on the feasibility of introducing a “differential pricing” for HIV/AIDS drugs in favour of developing countries.
• Document

  Equity in health sector responses to HIV/AIDS in Malawi

  EQUINET: Network for Equity in Health in Southern Africa, 2003

  In Malawi, HIV/AIDS has created an increasing demand for healthcare, exacerbated by population pressure, chronic poverty and food insecurity. This demand is set against a reduced capacity to supply healthcare.
• Document

  The costs of anti-retroviral treatment in Zambia

  Partners for Health Reformplus, 2003

  This report analyzes the costs and resource requirements associated with the provision of antiretroviral (ARV) therapy in the public health sector in Zambia.
• Document

  Intellectual property rights, anti-AIDS policy and generic drugs: lessons from the Brazilian public health program

  International AIDS Economics Network, 2003

  The paper analyses Brazil’s national anti-Aids programme. The focus is on the main choices that have governed the Programme’s preparation, the obstacles it has faced and how it has overcome them.
• Document

  Setting priorities for government involvement with antiretrovirals

  International AIDS Economics Network, 1997

  This paper examines four questions posed by economic analysis to help set priorities for government involvement with antiretroviral therapy for people living with HIV/AIDS. The main focus is on making decisions about policy relating to ARVs in developing countries where the needs are greatest and resource constraints are most binding.
• Document

  A commitment to action for expanded access to HIV/AIDS treatment

  World Health Organization, 2002

  This document describes the International HIV Treatment Access Coalition (ITAC) and the ways in which it is working to expand access in developing countries to HIV/AIDS treatment.The ITAC is a coalition between NGOs, government, foundations, the private sector, academic and research institutions and HIV sufferers to increase the availability and uptake of treatments.
• Document

  Antiretroviral treatment can be cost-saving for industry and life-saving for workers: a case study from Côte d’Ivoire’s private sector

  International AIDS Economics Network, 2003

  This paper aims to describe the health and economic impact of comprehensive HIV care with Anti-Retroviral Treatments (ART) within a private enterprise in Côte d’Ivoire.It describes how an “HIV solidarity fund” is used to finance ART to HIV-infected workers in Côte d’Ivoire.

Pages